Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 676 to 700 of 766

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugsTA225
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphomaTA226
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial diseaseTA223
Golimumab for the treatment of psoriatic arthritisTA220
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemiaTA218
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Bendamustine for the first-line treatment of chronic lymphocytic leukaemiaTA216
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 yearsTA213
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular eventsTA210
Prucalopride for the treatment of chronic constipation in womenTA211
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancerTA212
Trastuzumab for the treatment of HER2-positive metastatic gastric cancerTA208
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumoursTA209
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumoursTA86
Denosumab for the prevention of osteoporotic fractures in postmenopausal womenTA204
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)TA206
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)TA207
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis CTA200
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritisTA199
Capecitabine for the treatment of advanced gastric cancerTA191
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancerTA192
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemiaTA193
Human growth hormone (somatropin) for the treatment of growth failure in childrenTA188
Infliximab and adalimumab for the treatment of Crohn's diseaseTA187

Results per page

  1. 10
  2. 25
  3. 50
  4. All